Edward Pallister

Edward Pallister

Auto-generated profile, based on publicly available information

Edward Pallister

Analytical Sciences, BioPharmaceuticals Development, R&D, AstraZeneca, Cambridge CB21 6GH, U.K.

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
TWTomasz Witkos
Tomasz Witkos
WCWing Lee Chan
Wing Lee Chan
MJMerja Joensuu
Merja Joensuu
MRManuel Rhiel
Manuel Rhiel
EPEd Pallister
Ed Pallister
MLMartin Lowe
Martin Lowe
COPI is a key mediator of protein trafficking within the secretory pathway. COPI is recruited to the membrane primarily through binding to Arf GTPases, upon which it undergoes assembly to form coated transport intermediates responsible for trafficking numerous proteins, including Golgi-resident enzymes. Here, we identify GORAB, the protein mutated in the skin and bone disorder gerodermia osteodysplastica, as a component of the COPI machinery. GORAB forms stable domains at the trans-Golgi that, via interactions with the COPI-binding protein Scyl1, promote COPI recruitment to these domains. Pathogenic GORAB mutations perturb Scyl1 binding or GORAB assembly into domains, indicating the importance of these interactions. Loss of GORAB causes impairment of COPI-mediated retrieval of trans-Golgi enzymes, resulting in a deficit in glycosylation of secretory cargo proteins. Our results therefore identify GORAB as a COPI scaffolding factor, and support the view that defective protein glycosylation is a major disease mechanism in gerodermia osteodysplastica.

9 November 2020 in Analytical Chemistry
Verified
Journal Article
Closed access
EPEdward G. Pallister
Edward G. Pallister
MCMatthew S. F. Choo
Matthew S. F. Choo
IWIan Walsh
Ian Walsh
JTJien Nee Tai
Jien Nee Tai
STShi Jie Tay
Shi Jie Tay
TNTerry Nguyen-Khuong
Terry Nguyen-Khuong

24 May 2022 in Journal of the American Society for Mass Spectrometry
Verified
Journal Article
Open access
KGKatherine Gibson
Katherine Gibson
DCDale A. Cooper-Shepherd
Dale A. Cooper-Shepherd
EPEdward Pallister
Edward Pallister
SISophie E. Inman
Sophie E. Inman
SJSophie E. Jackson
Sophie E. Jackson
VLViv Lindo
Viv Lindo
There is an increasing emphasis on the critical evaluation of interbatch purity and physical stability of therapeutic peptides. This is due to concerns over the impact that product- and process-related impurities may have on safety and efficacy of this class of drug. Aspartic acid isomerization to isoaspartic acid is a common isobaric impurity that can be very difficult to identify without first synthesizing isoAsp peptide standards for comparison by chromatography. As such, analytical tools that can determine if an Asp residue has isomerized, as well as the site of isomerization within the peptide sequence, are highly sought after. Ion mobility-mass spectrometry is a conformation-selective method that has developed rapidly in recent years particularly with the commercialization of traveling wave ion mobility instruments. This study employed a cyclic ion mobility (cIMS) mass spectrometry system to investigate the conformational characteristics of a therapeutic peptide and three synthetic isomeric forms, each with a single Asp residue isomerized to isoAsp. cIMS was able to not only show distinct conformational differences between each peptide but crucially, in conjunction with a simple workflow for comparing ion mobility data, it correctly located which Asp residue in each peptide had isomerized to isoAsp. This work highlights the value of cIMS as a potential screening tool in the analysis of therapeutic peptides prone to the formation of isoAsp impurities.

4 January 2018 in ChemBioChem
Verified
Journal Article
Closed access
PDF file
KHKun Huang
Kun Huang
Fabio ParmeggianiFabio Parmeggiani
Fabio Parmeggiani
EPEdward Pallister
Edward Pallister
CHChuen‐Jiuan Huang
Chuen‐Jiuan Huang
FLFang‐Fang Liu
Fang‐Fang Liu
SFSabine L. Flitsch
Sabine L. Flitsch

20 March 2017 in Analytical Chemistry
Verified
Journal Article
Closed access
CGChristopher J. Gray
Christopher J. Gray
Antonio Sanchez RuizAntonio Sanchez Ruiz
Antonio Sanchez Ruiz
IŠIvana Šardzíková
Ivana Šardzíková
YAYassir A. Ahmed
Yassir A. Ahmed
RMRebecca L. Miller
Rebecca L. Miller
SFSabine L. Flitsch
Sabine L. Flitsch

3 October 2019 in Biochemistry
Verified
Journal Article
Closed access
EPEdward George Pallister
Edward George Pallister
MCMatthew S. F. Choo
Matthew S. F. Choo
JTJien-Nee Tai
Jien-Nee Tai
DLDawn S. Z. Leong
Dawn S. Z. Leong
WTWen-Qin Tang
Wen-Qin Tang
TNTerry Nguyen-Khuong
Terry Nguyen-Khuong